Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- JMA Calls for Investigation into Increasing Cases of Off-Label Use of GLP-1 Agents
March 4, 2022
- FPMAJ Starts Survey on Industry’s Inspection Status for “Stable Supply Medicines”
March 3, 2022
- JPMA, Overseas Pharma Groups Call for Improvements in Access to COVID-19 Vaccines
March 1, 2022
- Impact of Ukraine Invasion Limited in Japan? Trader Group Says Epirubicin Is Only API Possibly Affected
February 25, 2022
- FPMAJ Begins Survey on Lifting of Shipment Restrictions
February 24, 2022
- Chuikyo Payer Rep Wants Category-Based Debate on Adjustment Rate, Prods PMP Cuts in Next Off-Year Revision
February 24, 2022
- Takeda’s Ramona Sequeira Becomes 1st Female PhRMA Chair
February 15, 2022
- Govt-Industry Arrangement for Drug Supply Survey Hits Rough Waters; FPMAJ Stands Pat on Continued Dialogue
February 10, 2022
- PhRMA Taps Diplomat Hans Klemm as New Japan Representative
February 3, 2022
- Japan Market Should Grow in Single-Digit Range, Not Zero Growth: PhRMA Chair
January 31, 2022
- JPMA Embarking on Holistic Social Security Debate, Health Coverage Review: Chief
January 21, 2022
- CEA Process to Be Improved, but Operational Issues Remain: PhRMA/EFPIA
January 20, 2022
- JGA Chief Pledges to Restore Trust in Generics in 2022
January 14, 2022
- JPA Urges MHLW to Allow Access to List of Registered Pharmacies Carrying Lagevrio
January 14, 2022
- Osamu Kunii of Global Fund to Become New GHIT Fund CEO
January 13, 2022
- FPMAJ to Go Full Force on Honebuto Debate towards Next Off-Year Price Revision: Chief
January 6, 2022
- EFPIA Japan Taps Takeo Morooka as Director General
December 24, 2021
- Generic Use Rate Skids to 79.2% in July-September: JGA
December 24, 2021
- Japan Trade Groups Hail Progress in Reward for Innovation, but Fret Cost Disclosure Plans: FY2022 Reform
December 23, 2021
- INES Launches Cervical Cancer Awareness Project in Japan
December 10, 2021
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…